<DOC>
	<DOCNO>NCT01243424</DOCNO>
	<brief_summary>The aim study investigate longterm impact cardiovascular morbidity mortality , relevant efficacy parameter ( e.g. , glycaemic parameter ) safety ( e.g. , weight hypoglycaemia ) treatment linagliptin patient type 2 diabetes elevate cardiovascular risk receive usual care , compare outcome glimepiride .</brief_summary>
	<brief_title>CAROLINA : Cardiovascular Outcome Study Linagliptin Versus Glimepiride Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Type 2 diabetes 2 . Elevated glycosylated haemoglobin ( HbA1c ) : 6.5 8.5 % , inclusive , treatment naïve mono/dual therapy metformin and/or alphaglucosidase inhibitor ; 6.5 7.5 % , inclusive , treatment sulphonylurea/glinide mono dual ( metformin OR alphaglucosidase inhibitor ) therapy ) 3 . Preexisting cardiovascular disease OR specify diabetes endorgan damage OR age = &gt; 70 year OR two specify cardiovascular risk factor 4 . BMI = &lt; 45kg/m² 5. age &gt; = 40 = &lt; 85 year 6. sign date write ICF 7. stable antidiabetic background least 8 wks study start Exclusion criterion : 1 . Type 1 diabetes 2 . Treatment antidiabetic drug ( e.g . rosiglitazone , pioglitazone , Glucagonlike peptide 1 ( GLP1 ) analogue/agonists , Dipeptidylpeptidase IV ( DPPIV ) inhibitor insulin ) prior inform consent ( previous short term use insulin ( two week ) allow take least 8 week prior inform consent ) 3. treatment antiobesity drug le 3 month ICF 4. uncontrolled hyperglycemia 5. previous plan bariatric surgery intervention 6. current plan system corticoid treatment 7. change thyroid hormone treatment 8. acute liver disease impair hepatic function 9. preplanned coronary artery revascularization within 6 month ICF 10. know hypersensitivity component 11 . Inappropriateness glimepiride treatment renal safety issue accord local prescribing information 12. congestive heart failure class III IV 13. acute chronic metabolic acidosis 14. hereditary galactose intolerance 15. alcohol drug abuse 16. participation another trail IMP give 2 month IMP start 17. premenopausal woman nurse pregnant childbearing potential willing use acceptable method birth control 18. patient consider reliable investigator 19. acute coronary syndrome = &lt; 6 wks ICF 20. stroke TIA = &lt; 3 month prior ICF</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>